
    
      This research is being done to determine the negative re-biopsy rate as determined by
      MRI/TRUS fusion guided biopsy targeting the dominant nodule site defined by pre-treatment MRI
      following three months (90 days) of combination bicalutamide plus finasteride.
    
  